Astellas Pharma (JP:4503) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Astellas Pharma has withdrawn its marketing application for avacincaptad pegol, a treatment for geographic atrophy linked to age-related macular degeneration, from the European Medicines Agency. Despite positive results in the U.S., the company cites interactions with the EMA as the reason for this decision, while remaining optimistic about the drug’s clinical benefits and committed to global regulatory engagement.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue